Global Peptic Ulcer Drugs Market Size, Share, Forecast Report, 2020-2027

Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022.

The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics.
Key Players For Global Peptic Ulcer Drugs Market:
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals

Segments:
Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.